Abstract:Osteosarcoma recurrence following surgical resection is notoriously prevalent and resistant to chemotherapy (i. e., doxorubicin, DOX) due to its intricate immunosuppressive tumor microenvironment, which remains one of the most life-threatening tumors. In this study, we report the fabrication of an in-situ injectable hydrogelimmobilized nanotherapeutics, tailored to stimulate tumoricidal immunity, thus mitigate both localized osteosarcoma recurrence and the propagation of metastatic tumors subsequent to surgical intervention. Zeolitic imidazolate framework-8 nanoparticles (ZIF NPs), encapsulating a chemotherapeutic agent (i.e., DOX) and immunotherapeutic agents (i.e., alpha PDL1 and alpha CD47), are loaded in fibrin hydrogels. These bioengineered constructs are judiciously deployed at surgical sites to orchestrate chemo-immunotherapeutic interventions, effectuated through the controlled release of doxorubicin and the initiation of T cell-mediated immune responses. DOX has the capability to eradicate tumor cells and initiate immunogenic cell death. Notably, alpha PDL1 engenders the circumvention of PDL1-mediated resistance and dominates metastatic tumor expansion, thereby exerting a pivotal role in the context of systemic immunosuppression. alpha CD47 blocks the 'don't eat me' signaling axis intrinsic to cancer cells, thereby potentiating their phagocytosis by macrophages. This orchestrated blockade synergistically activates the host immune milieu, thereby repressing tumor recurrence and curtailing the growth of metastatic lesions post-surgical resection in the subcutaneous tumor model (lateral and bilateral) and tibial tumor model (orthotopic and metastatic), respectively. Additionally, zinc ions from the degradation of ZIF NPs acts as the stimulator of interferon genes (STING) agonists to enhance the immunotherapeutic activity against distal and metastatic tumors. The reported immune checkpoint-regulatable cancer immunotherapy activates the host innate and adaptive immune systems, which shows promising for the treatment of osteosarcoma patients.

IL-11Rα-targeted Nanostrategy Empowers Chemotherapy of Relapsed and Patient-Derived Osteosarcoma.

IL-11-Engineered Macrophage Membrane-Coated Reactive Oxygen Species-Responsive Nanoparticles for Targeted Delivery of Doxorubicin to Osteosarcoma

Reduction-responsive Polypeptide Nanomedicines Significantly Inhibit Progression of Orthotopic Osteosarcoma.

Hyaluronate-Based Self-Stabilized Nanoparticles for Immunosuppression Reversion and Immunochemotherapy in Osteosarcoma Treatment

Targeting of CXCR1 on Osteosarcoma Circulating Tumor Cells and Precise Treatment Via Cisplatin Nanodelivery

Synergistic treatment of osteosarcoma with biomimetic nanoparticles transporting doxorubicin and siRNA

Bio-inspired Cisplatin Nanocarriers for Osteosarcoma Treatment.

Targeting IL-11R/EZH2 signaling axis as a therapeutic strategy for osteosarcoma lung metastases

Targeted Chemotherapy for Subcutaneous and Orthotopic Non-Small Cell Lung Tumors with Cyclic RGD-functionalized and Disulfide-Crosslinked Polymersomal Doxorubicin

Targeted osteosarcoma chemotherapy using RGD peptide-installed doxorubicin-loaded biodegradable polymeric micelle

CPPs-modified chitosan as permeability-enhancing chemotherapeutic combined with gene therapy nanosystem by thermosensitive hydrogel for the treatment of osteosarcoma

A Nanodrug Combining CD47 and Sonodynamic Therapy Efficiently Inhibits Osteosarcoma Deterioration.

Enhancing Osteosarcoma Killing and CT Imaging Using Ultrahigh Drug Loading and NIR-Responsive Bismuth Sulfide@Mesoporous Silica Nanoparticles

Targeted delivery of PD‐L1‐derived phosphorylation‐mimicking peptides by engineered biomimetic nanovesicles to enhance osteosarcoma treatment

Co-delivery of siAEG-1 and doxorubicin to treat osteosarcoma via nanomicelles for azide-alkyne "click" conjugation of poly(l-lysine) dendrons onto Zein

Tumor Microenvironment-Responsive Hyaluronate-Calcium Carbonate Hybrid Nanoparticle Enables Effective Chemotherapy for Primary and Advanced Osteosarcomas

Immune Checkpoint-Regulatable Hydrogel-Immobilized Nanotherapeutics for Post-Surgical Treatment of Osteosarcoma

Self‐Stabilized Hyaluronate Nanogel for Intracellular Codelivery of Doxorubicin and Cisplatin to Osteosarcoma

Combination Therapy with Bioengineered Mir-34A Prodrug and Doxorubicin Synergistically Suppresses Osteosarcoma Growth.

Biomimetic Targeted Co‐Delivery System Engineered from Genomic Insights for Precision Treatment of Osteosarcoma

Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy